TOT BIOPHARM-B(01875) reported a 49% year-on-year increase in revenue to RMB 809 million in the first three quarters.

TOT BIOPHARM-B (01875) announced that during the nine-month period ending on September 30, 2024, the Group's operating income increased by 49% year-on-year to RMB 809 million, mainly due to the steady growth of sales of self-developed products and CDMO/CMO business. Net profit reached RMB 35.403 million.